Document is current
Any future updates will be listed below
-
Authors
Pratley, Richard E. http://orcid.org/0000-0002-2912-1389
Husain, Mansoor
Lingvay, Ildiko
Pieber, Thomas R.
Mark, Thomas
Saevereid, Hans A.
Møller, Daniel Vega
Zinman, Bernard
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01959529 at ClinicalTrials.govDocuments that mention this clinical trial
DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
https://doi.org/10.1007/s13300-018-0430-4
21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial
https://doi.org/10.2337/db20-21-lb
Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis
https://doi.org/10.2337/db18-1065-p
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes
https://doi.org/10.2337/dc18-2361
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1
https://doi.org/10.1016/j.ahj.2016.06.004
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
https://doi.org/10.1186/s12933-019-0960-8
Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
https://doi.org/10.1136/bmjdrc-2021-002339
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 14 August 2019
Accepted: 31 October 2019
First Online: 15 November 2019
Ethics approval and consent to participate
: The protocol was approved by independent ethics committees or institutional review boards for each center; written informed consent was obtained from each patient before any trial-related activities.
: Not applicable.
: REP’s fees for services were paid directly to AdventHealth (formerly Florida Hospital), a non-profit organization and therefore he has no financial relationship with the following companies, except for Sanofi. Consultancy and speaker fees from AstraZeneca, Takeda and Novo Nordisk; consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, Hanmi Pharmaceutical Co. Ltd., Janssen Scientific Affairs LLC, Ligand Pharmaceuticals, Inc., Eli Lilly, Merck, Pfizer and Eisai, Inc.; research grant from Gilead Sciences, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Inc., Eli Lilly, Merck, Sanofi US LLC and Takeda. MH has received consulting fees or honoraria from AstraZeneca, Boehringer-Ingelheim, Janssen, Merck and Novo Nordisk. IL received funds for research, consulting, editorial support and/or travel expenses from: Novo Nordisk, Eli Lilly, Sanofi, Astra Zeneca, Boehringer-Ingelheim, Merck, Novartis, Intarcia, MannKind, TARGETPharma, Pfizer, Valeritas and Mylan. TRP has received research support from Novo Nordisk and AstraZeneca (paid directly to the Medical University of Graz); personal fees as a consultant from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk and Roche Diabetes Care. TRP is also the Chief Scientific Officer of CBmed (Center for Biomarker Research in Medicine), a public-funded biomarker research company. HAS and DVM are full-time employees of Novo Nordisk A/S. TM is a full-time employee of, and holds stock in, Novo Nordisk A/S. BZ has received grant support from Boehringer-Ingelheim, AstraZeneca and Novo Nordisk; and consulting fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk and Sanofi.
